Population Pharmacokinetics and Exposure‐Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
ABSTRACT Ziftomenib, a potent, highly selective, oral menin inhibitor, has demonstrated significant clinical benefit and deep responses in relapsed and/or refractory (R/R) nucleophosmin 1‐mutated (NPM1‐m) acute myeloid leukemia (AML) patients. Here we present data from analyses conducted to characte...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley
2026-05-01
|
| Serie: | CPT: Pharmacometrics & Systems Pharmacology |
| Accesso online: | https://doi.org/10.1002/psp4.70244 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|